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ARTICLE INFO

ABSTRACT
Purpose: To identify incidence and predictors of stress urinary incontinence (SUI)
following Holmium laser enucleation of the prostate (HoLEP).
Materials and Methods: We performed a retrospective review of 589 HoLEP patients
from 2012-2018. Patients were assessed at pre-operative and post-operative visits.
Univariate and multivariate regression analyses were performed to identify predictors
of SUI.
Results: 52/589 patients (8.8%) developed transient SUI, while 9/589 (1.5%) developed
long-term SUI. tSUI resolved for 46 patients (88.5%) within the first six weeks and
in 6 patients (11.5%) between 6 weeks to 3 months. Long-term SUI patients required
intervention, achieving continence at 16.4 months on average, 44 men (70.9%) with
incontinence were catheter dependent preoperatively. Mean prostatic volume was
148.7mL in tSUI patients, 111.6mL in long-term SUI, and 87.9mL in others (p <0.0001).
On univariate analysis, laser energy used (p <0.0001), laser “on” time (p=0.0204),
resected prostate weight (p <0.0001), overall International Prostate Symptom Score
(IPSS) (p=0.0005), and IPSS QOL (p=0.02) were associated with SUI. On multivariate
analysis, resected prostate weight was predictive of any SUI and tSUI, with no risk
factors identified for long-term SUI.
Conclusion: Post-HoLEP SUI occurs in ~10% of patients, with 1.5% continuing beyond
six months. Most patients with tSUI recover within the first six weeks. Prostate size
>100g and catheter dependency are associated with increased risk tSUI. Larger prostate
volume is an independent predictor of any SUI, and tSUI.

INTRODUCTION
Benign prostatic hyperplasia (BPH) is a
common condition affecting many older men.
In the United States, more than 70% of men
aged 60-69 years have symptoms associated
with BPH. Currently, lower urinary tract symptoms (LUTS) impact almost 80% of men older
than 70 (1).
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Historically, transurethral resection of the
prostate (TURP) has been the gold standard for
endoscopic management of BPH (2). This technique, although effective, has many potential adverse effects and limitations which have prompted
the advent of newer treatment modalities for BPH
(3-5). Holmium-laser enucleation of the prostate (HoLEP) is one of the most prominent newer
modalities. HoLEP is size independent and can be
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used for enucleation of prostates over 100g, which
has traditionally been a limitation of TURP. Recent studies have shown that HoLEP is equally
as effective, and potentially more effective, when
compared to TURP and open simple prostatectomy
across a variety of outcomes (4).
With HoLEP now recognized in the AUA
guidelines as a viable alternative treatment option for those with moderate to severe LUTS, it is
important to understand better the adverse event
profile associated with this procedure (6). In our
institutional experience, the most common complication encountered with HoLEP is postoperative
stress urinary incontinence (SUI). The vast majority
of SUI seen after HoLEP is transient, with the majority of cases resolving within one year (7). We have
found that transient SUI (tSUI) represents one of the
most common complaints affecting patient satisfaction and the quality of life postoperatively. Recent
reports note that the rates of postoperative SUI
range between 1.4% and 44% following HoLEP
(8-11). The wide range in reported SUI rates is
most likely multifactorial and may be due to different operative techniques, surgeon experience,
and patient-specific factors. Unfortunately, many
of these studies are limited by small sample sizes
and technique heterogeneity.
With this study, we aim to more accurately define SUI rates using a large single-surgeon
single-institutional experience and to identify the
incidence and predictors of SUI following HoLEP.
With this knowledge, surgeons can better counsel patients regarding the procedure allowing for
more informed patient decision making and improve patient satisfaction.
MATERIALS AND METHODS
We performed an IRB approved (Control
#12D.50) retrospective chart review of all patients
undergoing HoLEP at our institution between January 2012 and June 2018. Our review included the
charts of all patient who underwent HoLEP at our
institution within this time period under the care of
a single surgeon. The exclusion criteria for this review include incomplete surgical resection and lack
of post-operative follow-up. Baseline demographic
data collected included age, body mass index (BMI),

serum prostate-specific antigen (PSA), prostate volume, peak Uroflow rate, mean Uroflow rate, PVR
volume, IPSS score, and IPSS QOL rating. All patients underwent urodynamic testing (Laborie Medical Technologies®) before undergoing surgery to
confirm the diagnosis of bladder outlet obstruction.
All procedures were performed by a single experienced surgeon (A.D.) who had performed more than
one thousand HoLEP cases before the study period.
Postoperative clinic visits were conducted within
two weeks, at six weeks, and at three months. Assessment at postoperative visits included the IPSS
questionnaire, PVR, and Uroflow testing.
Our trilobar HoLEP technique has been described previously, but in brief, a 26 French (Fr) continuous flow resectoscope with a laser bridge adapter
and an endoscopic camera are utilized (12). The laser
fiber is passed through a 6Fr open-ended ureteral
catheter. A 100 Watt holmium laser with an end-firing 550-micron laser fiber is used with energy
settings of 2.0J and 50Hz. After trilobar enucleation
is completed, a morcellator, grasper, or both are used
to clear the bladder of any prostatic tissue.
At postoperative visits, SUI was assessed
clinically, which was defined as incontinence during activity with a patient-reported negative impact on quality of life. Any patient who reported
incontinence which necessitated the utilization
of undergarment pads or diapers was considered
“incontinence”, while those who did not report
needing any pads or diapers were considered continent for our study purposes. SUI was differentiated from other forms of incontinence by careful
history taking and physical examination in the
clinic. Patients with different types of incontinence, such as urge or mixed, were excluded from
this study. For study purposes, SUI was considered
transient if it resolved within six months of the
procedure date, in following with previous literature (6). Any leakage beyond six months was
deemed to be long-term SUI.
Additional risk factors assessed included prostate size as measured by TRUS, CT, or
MRI imaging. Patients were risk stratified based
on preoperative prostate size (>100g or ≤100g)
and pre-operative catheter dependency status
(clean intermittent catheterization and continuous urethral drainage).
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Univariate analysis for baseline demographics and perioperative risk factors were completed
using the chi-square test for categorical variables
and ANOVA for comparison of continuous variables. Multivariable logistic regression was completed to identify factors predictive of increased risk for
any SUI, transient SUI, and long-term SUI after HoLEP. Significant factors from the univariate analysis
were included in the multivariable analysis. Analyses were completed using SPSS®, version 23.0.
RESULTS
Five hundred eighty nine men undergoing HoLEP during the study period were

identified. Postoperative tSUI occurred in 52
men (8.8%), while 9 (1.5%) had long-term SUI,
for a total of 61 (10.4%) patients who experienced any SUI after HoLEP. Of the patients who
experienced tSUI, all had their incontinence
resolved within three months. 46 men (88.5%)
with tSUI had full resolution of incontinence
within the first six weeks, while the remaining
6 men (11.5%) resolved between six weeks and
three months.
Table-1 highlights preoperative baseline characteristics as well as perioperative results. Except for pre-operative prostate size (tSUI: 148.7±56.8mL, long-term SUI:
98.0±50.1mL, no SUI: 92.2±50.6mL, p <0.0001),

Table 1 - Baseline Characteristics, Preoperative, and Perioperative Data.
Patients with no
SUI (n=528)

tSUI patients (n=52)

Long-term SUI (n=9)

p-value

Age

70.6±8.5

72.0±8.9

65.6±5.7

0.1027

BMI

28.7±7.8

29.6±5.8

28.2±4.1

0.7026

10.03±47.45

6.7±7.4

9.0±7.1

0.9388

92.2±50.6

148.7±56.8

111.6±48.5

<0.0001

Pre-Op Uroflow Peak Flow (mL/s)

8.6±9.9

14.7±23.5

11.5±10.8

0.0009

Pre-Op Uroflow Mean Flow (mL/s)

3.4±2.5

3.7±3.2

3.5±1.8

0.9367

238.8±249.2

297.0±298.1

185.2±112.3

0.3030

Pre-Op IPSS Results

19.7±8.5

17.9±9.8

19.4±5.8

0.5897

Pre-Op IPSS QOL Results

3.6±1.2

3.5±1.5

3.8±0.7

0.8231

201 (38.1%)

37 (71.2%)

7 (77.8%)

<0.0001

Laser Energy Used (kJ)

339.3±190.4

514.4±151.4

434.3±145.8

<0.0001

Laser On Time (min)

118.7±72.8

163.5±89.7

174.2±67.4

0.0204

70.2±42.8

135.5±70.5

103.2±52.4

<0.0001

Post-Op Catheterization Time (days)

5.5±3.5

4.9±2.1

6.6±4.6

0.6139

Post-Op Uroflow Peak Flow (mL/s)

24.3±17.6

24.0±11.6

24.8±9.5

0.9926

Post-Op Uroflow Mean Flow (mL/s)

6.4±4.8

5.1±3.2

6.4±1.7

0.6384

63.4±89.3

63.4±78.5

10.3±10.5

0.3414

Post-Op IPSS Results

6.8±5.9

9.5±8.3

16.7±11.4

0.0005

Post-Op IPSS QOL Results

1.1±1.4

1.8±1.4

2.4±2.0

0.0214

Preoperative Data

Serum PSA (ng/mL)
Prostate Size (mL)

Pre-Op Post Void Residual (mL)

Pre-operative Catheterization (N, %)
Perioperative Data

Resected Prostate Weight (g)

Post-Op Post Void Residual (mL)

Continuous data is presented as mean ± standard deviation; categorical data as proportions
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pre-operative Qmax (tSUI: 14.7±23.5mL/s, long-term SUI: 11.5±10.8mL/s, no SUI: 8.6±9.9mL/s,
p=0.0009) and pre-operative catheter dependence
(tSUI: 71.2% vs. long-term SUI: 77.8% vs. no SUI:
38.1%, p <0.0001), there was no significant difference between men who developed transient SUI,
long-term SUI, and those who did not.
With regard to perioperative and postoperative results, patients who developed SUI were
found to have greater laser energy used (tSUI:
514.4±151.4 kJ vs. long-term SUI: 434.3±145.8
kJ vs. no SUI :339.3±190.4 kJ, p <0.0001), longer
laser “on” time (tSUI: 163.5±89.7 min, long-term
SUI: 174.2±67.4 min, no SUI: 118.7±72.8 min,
p=0.0204), larger resected prostate weight (tSUI:
135.5±70.5g, long-term SUI: 103.2±52.4g, no
SUI: 70.2±42.8g, p <0.0001), higher overall IPSS
score (tSUI: 9.5±8.3, long term SUI: 16.7±11.4,
no SUI: 6.8±5.9, p=0.0005) and IPSS QOL scores
(tSUI: 1.8±1.4, long term SUI: 2.4±2.0, no SUI:
1.1±1.4, p=0.0214).
When patients with tSUI were stratified by
preoperative prostate volume of >100g (n=44) or
≤100g (n=8), 8 men (100%) with prostates ≤100g
had the resolution of tSUI within 6 weeks. In the
44 men with larger (>100g) prostates, 38 (86.3%)
had the resolution of tSUI within 6 weeks, while
the remaining 6 (13.6%) had the resolution between 6 weeks to 3 months. There was not a statistical significance (p=0.2394) in recovery time when
comparing larger prostates (>100g) to smaller
prostates (≤100g).
On multivariable logistic regression analysis, we performed multiple analyses looking for
predictive factors predisposing patients to any SUI
(Supplementary Table-1.1), tSUI (Supplementary Table-1.2), and long-term SUI (Supplementary Table-1.3). Results showed that only resected
prostate weight was a significant predictor of developing any SUI (HR 1.020, 95% CI 1.007-1.033,
p <0.05) and tSUI (HR 1.019, 95% CI 1.006-1.032,
p <0.05). There were no risk factors identified for
long-term SUI patients.
DISCUSSION
HoLEP has struggled to gain widespread
adoption within the urology community due to a

well-established steep learning curve, requiring up
to 50 cases to become proficient (11, 13, 14) The
potential development of tSUI has also been a limiting factor in its uptake. SUI, the involuntary
leakage of urine, is distressing and has been shown to decrease the quality of life in patients (15).
Patient distress likely plays a role in the avoidance
of this prostate reducing technique by surgeons.
In our study, we evaluated the incidence and predictors of SUI after HoLEP. We then
looked to compare our results to those of other
prostate reducing procedures in the literature. In
patients undergoing TURP, the incidence of long-term stress incontinence is rare (~1%), although
30-40% of patients have tSUI resolving within six
months (16, 17). On the other hand, in men undergoing open simple prostatectomy (OP), there is a
much higher incidence of long-term incontinence
ranging between 1-40% depending on the technique utilized, with more current data showing
20.2% of patients becoming permanently incontinent (18-21). Further studies have shown a 38.6%
incidence of tSUI in the three months following
simple prostatectomy (22). In comparison, the incidence of long-term and transient SUI in our single-surgeon series is 1.5% and 8.8%, respectively.
Our results suggest improved surgical outcomes
compared to the published literature.
Both HoLEP and simple prostatectomy
seek to provide complete enucleation of the adenoma. Our HoLEP technique involves endoscopic
dissection of the adenoma in a retrograde fashion,
from the distal to the proximal attachments. HoLEP allows for distal visualization of the adenoma,
compared to the blind approach taken with OP. We
feel that this visualization confers an advantage,
as visual landmarks allow for the surgeon to avoid
damage to the sphincter, and may play a role in
lower incontinence rates seen in HoLEP versus OP.
Variable tSUI rates after HoLEP have
been reported in the literature. Previous studies
have outlined this complication as occurring in
anywhere from 1.4-44% of patients, of which the
vast majority recover full continence by one year
(10, 11, 23). A more recent large cohort study from
Japan reported a tSUI rate after HoLEP of 16.6%,
which is more consistent with our series (8). However, while the extreme variation in reported SUI
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rates postoperatively is likely a function of small
sample sizes, variable operative experience, heterogeneous operative techniques, and possible
prior bladder dysfunction, our series has the advantage of being a large single-surgeon series.
Shah et al. assessed the amount of time required
to regain bladder control following HoLEP and
found that it took 42.3 days (24). These results
are consistent with our study, in which all patients who developed tSUI had complete a recovery by three months. We assessed if a larger
prostate size was associated with rate of tSUI recovery. All six patients who took over 6 weeks
to recover had large prostate volume, while no
patients took over 6 weeks with a low prostate
volume. Though the analysis did not show statistical significance (p=0.2394), the absolute numbers suggest that men with larger prostate may
have a slightly slower rate of recovery.
This study also sought to uncover risk
factors that may predispose patients to SUI,
both transient and long-term. There was a statistical difference seen amongst the three groups
on analysis for preoperative prostate size, preoperative Qmax, laser “on” time, laser energy
used, and resected prostate volume. A novel finding of our study was the association of preoperative catheter dependence with postoperative
incontinence. The cause of this correlation remains unknown, but it is possible that patients
requiring preoperative catheterization have
more severe BPH, and therefore require longer
endoscopic manipulation, which predisposes the
patients to SUI. The only prior study looking
at risk factors by Nam et al. identified increasing age and operative time as risk factors (25).
However, on our multivariate logistic regression
analysis, only resected prostate weight was a
significant predictor of developing any SUI (HR
1.020, 95% CI 1.007-1.033, p <0.05) and tSUI
(HR 1.019, 95% CI 1.006-1.032, p <0.05).
Our study showed the rate of long-term
incontinence to be very low. While no preoperative risk factors predisposing patients to long-term
SUI were identified on multivariate regression,
post-analysis chart review of these 9 patients uncovered a high rate of neurological comorbidities.
Further investigation showed that 8/9 (88.9%)

patients had a significant neurological history.
However, as we cannot accurately capture the incidence of neurological comorbidities that exist
within the rest of the population, a comparison
was not possible. Of the 8, 7 had spinal pathology, including spinal stenosis and degenerative disc
disease, while 1 had myasthenia gravis. Critically,
all of these patients were able to achieve either
complete resolution of SUI or reduction to less
than 2 pads/day. The management strategies for
these patients included initial pelvic floor exercise therapy, and in those still unsatisfied, coaptite
injections. Multiple coaptite injections were given to patients who had partial responses. Only
one patient went on to require AUS implantation.
These 9 patients achieved a satisfactory level of
continence at an average of 16.4 months after the
completion of their HoLEP.
When assessing postoperative QOL outcomes, we found that men with tSUI and long-term
SUI had worse postoperative IPSS scores (both
worse subjective symptoms and quality of life
responses) when compared to those patients who
did not experience tSUI. As expected, SUI had a
substantial negative impact on quality of life. This
result is in line with previous reports showing the
quality of life impact that incontinence can have
on patients (26).
One possible cause of incontinence seen
after surgery is sphincter dysfunction, which is
likely the result of prolonged endoscopic manipulation. Endoscopic procedures are thought to
cause trauma directly to the sphincter, leading
to this dysfunction. This dysfunction is thought
to be temporary, causing the transient nature of
the SUI (8, 11, 27) A larger prostate size leads to
longer operative times, which may explain the
correlation between tSUI and both larger prostates and longer operative times. The longer laser
time and laser energy used, as well as the heavier
weight of resected prostate tissue, are all associated with a larger prostate. All of our results
seem to indicate that larger prostates cause longer operations, and therefore increased endoscopic manipulation and risk for tSUI via sphincter
dysfunction. As many of the variables associated
with tSUI on univariate analysis were surrogate
markers of prostate size, this may explain why
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they were not independently associated with tSUI
on multivariate regression analysis.
This study is not devoid of limitations,
including those inherent to a retrospective study.
SUI characterization was primarily dependent on
physician documentation. Missing data, especially
from operative variables, also limited the robustness of the multivariable analysis. Comorbidities,
such as diabetes, that may have been associated
with SUI development were not adequately captured.
Regardless of these limitations, this study
still represents the largest single-surgeon experience with HoLEP and provided valuable data regarding the incidence, time course and predictors
of post-operative tSUI. Transient SUI after HoLEP
has notable implications for patient quality of life,
which may contribute to the hesitancy in the widespread adoption of HoLEP. Our study demonstrates this tSUI resolves in the majority of patients,
usually within the first six weeks. Furthermore, by
identifying risk factors that predispose patients to
tSUI, preoperative counseling can be enhanced,
thus mitigating possible patient frustration and
improving both patient and physician satisfaction.
This may also provide data for better patient selection in order to avoid these complications after
the HoLEP procedure. We feel this study shows the
need for future prospective trials and further inquiry into ways to prevent this complication.

ABBREVIATIONS
SUI = Stress urinary incontinence
tSUI = Transient stress urinary incontinence
HoLEP = Holmium laser enucleation of prostate
BPH = Benign prostatic hyperplasia
LUTS = Lower urinary tract symptoms
TURP = Transurethral resection of prostate
PVR = Post-void residual
OP = Open prostatectomy
Qmax = Peak flow
IPSS = International prostate symptom score
QOL = Quality of life
PSA = Prostate-specific antigen
Fr = French
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Supplementary Table 1.1 - Results from multivariable logistic regression analysis assessing for risk factors for any SUI in
HoLEP patients.
Variables

OR (95% CI)

p

Age (years)

0.981 (0.928-1.037)

0.494

BMI (Kg/m2)

0.983 (0.923-1.047)

0.597

Prostate Volume (mL)

1.009 (0.997-1.021)

0.133

Laser Energy Used (Kj)

0.990 (0.996-1.003)

0.763

Laser On Time (min)

0.997 (0.990-1.005)

0.463

Resected Prostate Volume (cc)

1.020 (1.007-1.033)

0.002

Supplementary Table 1.2 - Results from multivariable logistic regression analysis assessing for risk factors for tSUI
in HoLEP patients.
Variables

OR (95% CI)

p

Age (years)

1.013 (0.949-1.083)

0.694

BMI (Kg/m2)

0.987 (0.925-1.054)

0.697

Prostate Volume (mL)

1.011 (0.997-1.025)

0.113

Laser Energy Used (Kj)

1.001 (0.996-1.006)

0.731

Laser On Time (min)

0.995 (0.986-1.004)

0.259

Resected Prostate Volume (cc)

1.019 (1.006-1.032)

0.004

Supplementary Table 1.3 - Results from multivariable logistic regression analysis assessing for risk factors for longterm SUI in HoLEP patients.
Variables

OR (95% CI)

p

Age (years)

0.915 (0.825-1.014)

0.090

2

BMI (Kg/m )

0.964 (0.830-1.120)

0.630

Prostate Volume (mL)

1.002 (0.978-1.026)

0.896

Laser Energy Used (Kj)

0.997 (0.990-1.003)

0.345

Laser On Time (min)

1.006 (0.994-1.019)

0.308

Resected Prostate Volume (cc)

1.009 (0.985-1.034)

0.456
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